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Nonsyndromic cleft lip with or without cleft palate (NSCLP) is a common birth
defect with a multifactorial etiology. Despite decades of research, the genetic underpinnings
of NSCLP still remain largely unexplained. A genome wide association study (GWAS) of a
large NSCLP African American family with seven affected individuals across three
generations found evidence for linkage at 8q21.3-24.12 (LOD = 2.98).

This region

contained three biologically relevant candidate genes: Frizzled-6 (FZD6) (LOD = 2.8),
Matrilin-2 (MATN2) (LOD = 2.3), and Solute Carrier Family 25, Member 32 (SLC26A32)
(LOD = 1.6). Sequencing of the coding regions and the 5’ and 3’ UTRs of these genes in
two affected family members identified a rare intronic variant, rs138557689 (c.153+432A>C), in FZD6. The rs138557689/C allele segregated with the NSCLP phenotype;
in silico analysis predicted and EMSA analysis showed that the 138557689/C allele creates
new DNA binding sites.

FZD6 is part of the WNT pathway, which is involved in

craniofacial development, including midface development and upper lip fusion. Our novel
findings suggest that an alteration in FZD6 gene regulation may perturb this tightly
controlled biological pathway and in turn contribute to the development of NSCLP in this
family. Studies are underway to further define how the rs138557689/C variant affects
expression of FZD6.
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INTRODUCTION
Isolated or nonsyndromic cleft lip with or without cleft palate (NSCLP) is the fourth
most common birth defect affecting more than 4,000 births each year in the United States
[1,2,3]. Despite the improvements in treatment, NSCLP has considerable medical and
financial implications for the affected individuals and their families, and the effects on
speech, hearing, and appearance can lead to adverse psychosocial and psychiatric outcomes
[4,5,6]. Individuals with NSCLP require multidisciplinary team care through adulthood and
continue to demonstrate increased morbidity and mortality rates compared to the general
population [7,8].
Cleft lip and palate has been recognized and documented throughout history. First
evidence of clefting was noted in an Egyptian mummy dating from 2400 to 1300 BC [9]. A
2000-year-old statue of a Columbian king, a 2000-year old African mask, a Ming dynasty
painting, and a 20th century Russian painting all depicted orofacial clefts [9]. What appears
to be the first documented treatment of cleft lip and palate was performed in 390AD by a
Chinese physician [10].
Many different explanations for causation of cleft lip and palate have evolved among
the various cultures and populations in the world. Causes are often attributed to maternal
impressions or supernatural events [11]. The term “hare-lip” to describe cleft lip originated
from beliefs that clefting results from eating or looking at a rabbit [12,13]. A prevailing
belief in many cultures is that a child will be born with a birth defect, including cleft lip and
palate, if a woman pities or makes fun of an affected individual while pregnant [13,14,15].
Supernatural causes, such as the effect of the moon (lunar eclipse), are alleged causes of
cleft lip and palate in Mexican folklore and among Hispanic populations [14,15,16], while
populations in India and Nigeria ascribed the cleft to “God's will”, evil and ancestral spirits,
1

or sins committed in past lives [17,18]. Thesis work of Fogh-Andersen in 1942 was the first
to widely recognize the hereditary component of CLP [19].
Despite the fact that NSCLP has been part of human life for many centuries, and the
fact that many beliefs for the causation of this birth defect exist, the etiology of NSCLP is
still largely unknown. Continual research in this area is needed to help elucidate the
underlying etiologies of this common birth defect in order to improve genetic counseling for
recurrence, diagnosis, prevention, and treatment, as well as to improve our understanding of
the development of clefts.

Classification of Clefts
Orofacial clefts are divided into two groups based on developmental origin: anterior
and posterior clefts [20]. Anterior cleft anomalies include cleft lip (CL) only, or cleft lip and
primary palate (CLP) [20]. Anterior clefts can extend through the lip and alveolar part of
the maxilla (primary or hard palate) to the incisive fossa [20]. Posterior cleft anomalies,
which include clefts of the secondary or soft palate, present as cleft palate only (CPO) [9,20]
Posterior clefts extend through the soft and hard sections of the palate to the incisive fossa
[20].
Clefts can further be divided into syndromic or nonsyndromic. Syndromic clefts are
distinguished by the presence of other congenital malformations and may be associated with
specific genes, chromosomal abnormalities, or maternal teratogenic exposures [21].
Approximately 30% of CLP and 50% of CPO are associated with other syndromes or
anomalies, and there are currently over 400 different conditions listed on Online Mendelian
Inheritance of Man in which clefts occur (http://www.ncbi.nlm.nih.gov/omim) [21]. Table 1
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is an abbreviated list of syndromes which have CLP or CPO as a phenotypic finding and the
genes associated with them. The remaining 70% of cases of CLP and 50% of cases of CPO
are isolated, and therefore are referred to as nonsyndromic [21]. Nonsyndromic CLP
(NSCLP) is the focus of this study.

A cleft can be unilateral, occurring on one side of the face, or bilateral, occurring on
both sides of the face. Unilateral clefts account for 90% of CLP (~60% of which occur on
the left side) while bilateral clefts account for the remaining 10% [21].
Recurrence of syndromic CLP depends on the underlying genetic condition, while
recurrence risk for NSCLP depends on several factors including number of affected
individuals in family, relation of affected family member, and laterality of the cleft [22].
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The empirical recurrence risk for siblings is 2-3% in a case of unilateral CLP and 3-5% in
the case of bilateral CLP [22].

Birth Prevalence
Cleft lip with or without palate is estimated to occur in approximately 1/700 to
1/1000 births but the prevalence of clefts varies by ethnicity [21,23]. The frequency of
NSCLP appears to be highest among Native Americans (~3.6/1000 births) followed by
Japanese (~2.1/1000 births) and Chinese (~1.7/1000 births) populations, and appears to be
the lowest among African derived populations (~0.3/1000 births) [9]. In Texas, the
prevalence of NSCLP is 0.67/1000 for Non-Hispanic Whites, 0.63/1000 for US-born
Hispanics, 0.65/1000 for non-US born Hispanics, and 0.40/1000 for African Americans [1].
Birth prevalence of NSCLP also varies by gender with a 2:1 male to female ratio
[24]. An association between NSCLP and socioeconomic status is implicated by studies
which show groups from rural, lower socioeconomic areas having a higher birth prevalence
of NSCLP compared to ethnically similar groups within higher socioeconomic status [21].
The birth prevalence of isolated CPO is approximately 1/2000 births and does not
appear to differ much between various ethnicities [21]. In contrast to NSCLP, there is a
female predominance of isolated CPO with a 3:2 female to male ratio [25].

Normal Development of the lip and palate
Understanding of normal development of the upper lip, primary, and secondary
palates is important to help explain the reason for the altered development seen in CLP.
Normal craniofacial development is a complex process directed by intricate pathways
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important for cell induction, differentiation, proliferation, migration, patterning, and
apoptosis [8,26]. Molecular pathways, including the Bmp, Fgf, Shh, and Wnt pathways,
coordinate craniofacial development through both synergistic and antagonistic signaling
[26]. Numerous genes, which code for growth factors, transcription factors, cell adhesion
molecules, and signaling molecules, strictly regulate the development of the face
[19,27,28,29,30]. Theoretically, perturbations within any of these genes and pathways could
alter craniofacial morphogenesis and result in clefting.
The human face begins developing in the 4th week of embryogenesis [28]. Neural
crest cells (NCCs), which are the major source of connective tissue components, migrate
from the neural folds and combine with the core mesoderm and the epithelia to establish five
facial primordia [20,26]. As depicted in Fig. 1a, the primodia consist of a single frontonasal
prominence, two mandibular and two maxillary prominences, all of which surround the
primitive oral cavity [8,28]. Ectodermal thickenings form nasal placodes and results in the
formation of nasal pits by the end of week 4. The nasal pits further divide the frontonasal
prominence into two horseshoe-shaped medial and lateral nasal processes (Fig. 1b) [8,26].
Rapid growth of the underlying mesenchyme of the facial primordia causes the
medial nasal prominences to merge with each other and with the maxillary and lateral nasal
prominences between the 7th to 10th week of embryogenesis [20]. The contact epithelia
between the prominences are broken up by cell apoptosis to give rise to the intermaxillary
segment from which the philtrum of the upper lip, the premaxillary part of the maxilla and
the primary palate are formed (Fig. 1c) [20,26].
The secondary palate, which comprises majority of the soft palate, except for the
anterior portion that holds the incisor teeth, has a different developmental origin [20].
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Palatal shelves, which originate from the maxillary processes, appear in the 6th week of
development and grow downward, vertical to the sides of the developing tongue (Fig. 1d)
[8,9]. The palatal shelves then elevate to a horizontal position above the tongue (Fig. 1e),
and fuse together (Fig. 1f) [8,20]. This is thought to occur earlier in females then in males
[9]. Additionally, the two palatal shelves merge with the primary palate and the nasal
septum dividing the oral from the nasal cavity [8]. This process is complete by the end of
the 10th week [9,20].

Development of Cleft Lip and Palate
Cleft lip and palate can result when any of the multifaceted factors involved in
normal facial morphogenesis are disrupted or altered. These may include failure of fusion of
6

the processes that form the face, distortions in epithelial movement, deficiency in epithelial
and mesenchymal transformation (EMT), or failure in apoptosis [26].
Deficiency of mesenchyme in the maxillary prominence(s) and the median palatal
process leads to anterior clefts [20]. Failure of one maxillary prominence to unite with the
two merged medial nasal prominences results in unilateral cleft of the upper lip, while
failure of both maxillary prominences to unite with the merged medial nasal prominences
results in bilateral cleft of the upper lip [9,20].
Defective development of the secondary palate leads to posterior palatal clefts [20].
This is mainly due to the failure of mesenchymal masses in the lateral palatal processes to
meet and fuse with each other and the nasal septum [9,20].

Treatment of NSCLP
Treatment of a patient with CLP requires a multidisciplinary approach which
includes craniofacial and maxillofacial surgery, dentistry and orthodontic, audiology,
otolaryngology, speech and language, nursing, pediatrics, genetics, and social services [31].
Many different surgical protocols exist to repair CLP and treat ensuing complications [21].
Currently, however, there is not an internationally accepted protocol for CLP repair [32].
Surgical repair of the CLP usually occurs within the first six months of life, the
general rule being to perform surgical repair when the child is approximately 10 weeks of
age, weighs at least 10 lb, and has achieved serum hemoglobin of 10 mg/ml [33]. There are
various techniques of CLP repair which have been refined throughout time and some of
these include LeMesurier (1955), Tennison (1952), Millard (1950), Skoog (1969), Randall
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(1990) and Brauer (1985). The choice of technique, however, most often depends on
surgeon preference and severity of cleft [21].

Etiology of NSCLP
NSCLP does not follow a traditional Mendelian pattern of inheritance but is believed
to result from a combination of several genetic variants which act in an additive fashion and
interact with the environment to produce the phenotype [21]. NSCLP is therefore
considered to be a multifactorial disorder that results from the interaction of both genetic
and environmental factors [21]. Genetic evidence for NSCLP comes from multiple studies.
These studies show that NSCLP aggregates in families, that there is a family history for
clefting in 24-33% of NSCLP patients with a 10 to 32-fold increase in recurrence risk to first
degree relatives, that the heritability of NSCLP in the NHW population is approximately
76%, and that the rate of concordance is higher in monozygotic (25-40%) than dizygotic (36%) twins [9,21,34,35,36,37,38,39]. Various environmental factors have also been
associated with an increased risk for NSCLP including smoking, alcohol, diet, infections,
fever, drugs, and teratogenic agents during early pregnancy [21,40,41,42,43].
Only a handful of genes associated with NSCLP have been identified to date and
these comprise approximately 20% of the genetic causes of NSCLP [44]. Interferon
regulator factor 6 (IRF6) is one of the genes that has shown an association with NSCLP in
multiple populations [45,46,47,48,49,50]. Mutations in IRF6 are also known to cause van
der Woude syndrome [51]. Various other genes, which include growth factors (TGFα,
TGFβ), transcription factors (MSX1, TBX22), genes involved in xenobiotics (CYP1A1,
GSTM1, NAT2), and other genes (RARA, MTHFR, CRISPLD2), have also been associated
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with NSCLP [52,53,54,55,56,57,58,59,60,61]. The constant identification of novel genes
for the pathogenesis of NSCLP across various populations highlights the genetic
heterogeneity of this complex birth defect.

Gene identification in NSCLP
Multiple genetic approaches have been used to identify the genes and pathways
contributing to NSCLP. These approaches include assessment of mouse models, linkage
analysis using large multiplex families and affected relative pairs, association studies using
family-based or case-control samples, identification of chromosomal anomalies or
microdeletions in affected cases, and candidate gene studies [62].
Recently, genome-wide association studies (GWAS) have expanded the research in
NSCLP and markedly helped in the identification of new candidate genes. GWAS studies
use known single nucleotide polymorphisms (SNPs) that cover the genome to identify
regions that are linked to and/or associated with NSCLP [62]. Identification of candidate
genes by GWAS permits further analysis of individual genes through direct sequencing [62].
Sequencing of the candidate genes allows for identification of sequence variants within the
gene which could potentially contribute to the development of NSCLP [62]. The sequence
variants can be located within protein coding regions as well as noncoding regions, which
include promoter/enhancer regions, or introns of the gene [63].

8q21.3-24.12 Chromosomal Region
A GWAS study performed in 2009 identified a major locus for NSCLP on
chromosome 8q24 but the region with highest linkage did not contain any protein coding
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genes [64]. Subsequent GWAS studies confirmed the association with the 8q24 locus and
identified additional loci including 10q25, 7q22, 20q12, and 1p22 [62]. A smaller GWAS
study reported by Chiquet et al. evaluated 10 multiplex NSCLP families including one large
African-American family with 11 affecteds across 3 generations (Fig. 2). It was performed
to confirm existing and identify new NSCLP chromosomal regions [65]. The study found
evidence for linkage on 8q21.3-24.12 (LOD=2.98) [65]. Further evaluation of this region
using linkage analysis generated a maximum multipoint LOD score of 2.8 for SNPs in
Frizzled 6 (FZD6), 2.3 in Matrilin-2 (MATN2), and 1.6 in Solute carrier family 25, member
32 (SLC26A32), prompting further analysis of these three genes and their connection to
NSCLP.
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Frizzled-6 and WNT pathway
Human Frizzled-6 (FZD6) gene maps to chromosome 8q22.3-q23.1 and encodes a
706 amino-acid seven-pass transmembrane protein with a cystine-rich domain in the Nterminal extracellular region, two-N linked glycosylation sites, and two cystine residues in
the second and third extracellular loops [66]. A total of 7 exons, 6 of which are coding,
comprise the FZD6 gene [66]. FZD6 amino acid sequence is well conserved between mouse
and human genes with an amino acid identity of 83.3% [66].
FZD6 is part of the Frizzled gene family which code for a group of receptors critical
for initiation of wingless-type (WNT) signaling pathway [67]. The Frizzled receptors share
conserved features which include a cystine-rich domain in the N-terminal extracellular
region implicated in the binding of WNT ligands, N-linked glycosylation sites, two cystine
residues in the second and third extracellular loops, and a Ser/Thr-x-Val motif in the Cterminus which acts as a binding site for the cytoplasmic protein containing the PDZ domain
[66,68,69].
FZD6 codes for three mRNA isoforms that are detected in both adult and fetal
tissues [70]. FZD6 was shown to be important for hair patterning in both Drosophila and
mice as well as mice claw morphogenesis and appears to act within the WNT/PCP (planar
cell polarity) pathway [71,72,73]. Mutations in FZD6 have been associated with isolated
autosomal recessive nail dysplasia and open neural tube defects in humans [71,74,75].
WNT signaling regulates differentiation and proliferation of a variety of cell types
during development and is an important regulator of various functions within the cells [76].
Signaling by the WNT pathway directs cell proliferation, cell polarity, and cell fate
determination during embryogenesis and homeostasis, regulates multiple developmental
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processes, and plays a critical role in embryogenesis through both canonical (β-catenin
dependent) and noncanonical (WNT/PCP and Ca2+/CAMKII) signaling [76,77].
The canonical/ β-catenin pathway is the best understood. As depicted in Fig. 3a,
when a WNT ligand is absent, cytoplasmic β-catenin forms a complex with the scaffolding
protein Axin, the tumor suppressor adenomatous polyposis coli gene product (APC),
glycogen syntahse kinase 3B (GSK3B) and casein kinase 1 (CK1), and is phosphorylated by
CK1 and subsequently by GSK3B [67]. Phosphorylated β-catenin is then recognized by the
E3 ubiquitin ligase (UB), and is targeted for degradation within the proteosome [78]. This
degradation, in turn, prevents β-catenin from reaching the nucleus, where the WNT target
genes are repressed by the DNA-bound T cell factor/lymphoid enyhancer factor (TCFTLE)/Groucho and histone deacetylases (HDAC) [67].
Transcription of WNT target genes is activated in the presence of WNT ligand. As
shown in Fig. 3b, the WNT ligand binds to a receptor complex formed between Frizzled and
low-density lipoprotein receptor related protein 5 or 6 (LRP5/6). This complex then recruits
a scaffolding protein Dishevelled (Dvl) and leads to LRP5/6 phosphorylation and Axin
recruitment [67,77]. This interrupts Axin-mediated phosphorylation and subsequent
degradation of β-catenin, and allows β-catenin to build up in the nucleus where it can
activate TCF/LEF and initiate transcription of WNT responsive genes [67].
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In contrast to other Frizzled receptors, FZD6 protein lacks the Ser/Thr-X-Val motif
at the C-terminal common to other frizzled receptors and has been shown to repress
canonical WNT signaling through the noncanonical Ca2+/CaMKII pathway by inhibiting
the TCF/LEF binding activity and down-regulating β-catenin targeted transcription of WNT
genes [66,70]. Removal of FZD6’s N or C terminal sequences, however, abolishes the
repressive activity of the protein [70].
Mutations in the WNT pathway have been linked to a variety of birth defects,
cancers, and other diseases [67]. Importantly, WNT signaling has been shown to play a role
in craniofacial development, including regional specification in the vertebrate face, neural
crest induction and differentiation, mid-face development and upper lip fusion in mice, and
13

facial morphogenesis in mice [26,79,80,81,82,83,84,85]. Craniofacial abnormalities,
including orofacial clefts, are found in WNT knockout mice and zebrafish [86,87]. An
association with individual WNT genes and NSCLP has been found in humans (WNT3,
WNT3A, WNT5A, WNT7A, WNT8A, WNT9B and WNT11) [87,88,89,90]. Based on this
information, FZD6 is a strong candidate gene for NSCLP. Coding mutations or variants in
the regulatory regions of FZD6 may alter the tightly regulated WNT pathway, and in turn
contribute to NSCLP.

Matrilin-2 and the extracellular matrix assembly
Matrilin-2 (MATN2) gene maps to chromosome 8q22.1-q22.3 and encodes a 956
amino-acid protein whose structure consists of a putative signal peptide, two von
Willerbrand factor A (vWFA)-like domains parted by ten epidermal growth factor (EGF)like domains, a unique segment not seen in other matrilins, and an α-helical coiled-coil (CC)
domain [91,92,93]. MATN2 has 19 exons and is transcribed from two alternative
promoters, one of which is an upstream housekeeping-type promoter functional in
fibroblasts and other cell types, and a downstream TATA-like promoter restricted to only
embryo fibroblast and certain cell lines [94]. Matrilin-2 protein functions as a part of a
tightly regulated pathway in the extracellular matrix (ECM) assembly and it is found in a
wide variety of connective tissue cells, smooth muscle cells, and both the dermis and the
epidermis in humans [93,95]. Human and mice Matrilin-2 proteins show 86.5% identity
[93].
Matrilin-2 belongs to a family of four ECM proteins (matrilin-1, -2, -3, and -4), all of
which share a structure made of vWFA and EGF domains, and a α-helical CC segment [92].
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The matrilin genes also share a phase I, U-12-type AT-AC intron that is located in a strictly
conserved position that separates the two exons for the CC domain [94]. While matrilin-1
and matrilin-3 are expressed mainly in cartilage and skeletal tissue, matrilin-2 and -4 have
wider tissue distribution, including some non-skeletal tissues [91]. Matrilins -1, -2, and -3
can form filamentous networks that can connect to collagen fibers [93]. While Matrilin-2 is
expressed in the mesoderm and epithelium in mice it is expressed in the dermal side of the
basement membrane at the dermal-epidermal junction, as well as in keratinocytes and
fibroblasts in humans [95].
Mutations in MATN3 gene were found to be associated with autosomal dominant
forms of multiple epiphyseal dysplasia (MED) and mutations in MATN1 have been
associated with osteoarthritis and relapsing polychondritis. MATN2 and MATN4, to date,
have not been associated with any disease [92,96]. Knock-out mice lacking Matn2 have
been shown to develop without any obvious abnormalities [97]. Few disorders, including
Klippel-Fiel syndrome with laryngeal malformations and Cohen syndrome (which consists
of facial, oral, ocular, and limb deformities, and well as intellectual disability), have been
linked to the 8q22 position [93]. MATN2, however, has not been identified as a candidate
gene in these syndromes [93].
Despite the lack of obvious craniofacial phenotype in Matn2 knock-out mice,
interactions of ECM components, growth factors, and embryonic tissues are known to be
involved in the normal development of cranial priomordia and orofacial structures [98,99]
and alterations in the ECM components could potentially lead to NSCLP.
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Solute carrier family 25, member 32 and Folate metabolism
Solute carrier family 25, member 32 (SLC25A32) gene, also called Mitochondrial
Folate Transporter (MTF), is located on chromosome 8q21.2. SLC25A32 consists of 7
exons and encodes a 315 amino-acid protein transporter which shuttles folates from the
cytoplasm into the mitochondria [100]. The protein consists of six transmembrane domains:
three loops facing the mitochondrial matrix and three repeats of an energy transfer sequence
[100]. The protein does not contain an ATP-binding motif and probably functions as an
ATP-independent transporter [100].
Solute carriers are comprised of 43 identified families which control the movement
of various substances across the cell membrane [101]. Members of the solute carrier family
25 (SLC25) are known to transfer a variety of substances across the mitochondrial
membrane, and are therefore referred to as mitochondrial solute carriers [102]. The
SLC25A32 protein is shown to transport folate across the mitochondrial membrane [100].
Folate metabolism is a complex process consisting of multiple genes and pathways.
Folate is absorbed from the environment, transported across the cell membrane, and
compartmentalized between the mitochondria and the cell cytoplasm before it is transported
into the mitochondria [103]. The transport of folate into the mitochondria involves various
transporters and carriers, including the SLC25A32 transporter [100,103].
The importance of folate in prevention of birth defects has been investigated since
folate fortification reduced the occurrence of spina bifida, an open neural tube defect
(ONTD), by approximately 70% [104]. Because ONTDs and NSCLP both develop from
migrating neural crest cells, studies have been performed to assess the role of folic acid in
NSCLP in hopes to validate the hypothesis that folic acid deficiency may also contribute to
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NSCLP [105,106]. Observational studies of folic acid supplementation and the recurrence
of NSCLP have not reliably shown the same decrease as with ONTD. A few meta-analysis
studies, however, showed decreases of 18-23% in the risk of NSCLP with supplementation
of folic acid and/or multivitamins during pregnancy [107,108]. Studies also suggest that
variations in the folate pathway genes may contribute to NSCLP [105]. Disturbances in the
folate transport, therefore, may also contribute to NSCLP.

Significance of this study
NSCLP is a common birth defect caused by both genetic and environmental factors.
Despite decades of research, genetic contributions to NSCLP have yet to be explained, and
there remains the need to identify candidate genes. The goal of this project is to further
elucidate the genetic etiology of NSCLP by sequencing the coding and 5’ and 3’ UTR
regions of three biologically relevant candidate genes, FZD6, MATN2, and SLC25A32,
previously identified in a genome wide scan in a large multiplex African-American family.
This family is unique because NSCLP has a low prevalence in the African American
population yet there are numerous affected individuals in multiple generations. Sequence
variants in any of these three genes may disrupt the highly regulated craniofacial
development and give rise to NSCLP. Identification of new genes for NSCLP would not
only benefit in diagnosis, prevention, and counseling for this birth defect, but may help in
understanding the developmental pathways involved in craniofacial morphogenesis.
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MATERIALS AND METHODS
IRB Approval
This study was approved by the Committee for the Protection of Human Subjects at
the University of Texas Health Science Center at Houston (HSC-MS-03-090 and HSC-MS11-0336).
Family
The focus of this study is an African American NSCLP family with 11 affected
individuals, 7 of whom were available for evaluation (Fig. 2). All family members were
evaluated by one author (JTH). No other anomalies or lip pits were present in any family
members. DNA samples from these 7 individuals and 13 connecting or related unaffected
family members were subjected to a previously described 6K Illumina IVb genome scan and
linkage analysis [65]. A maximum multipoint LOD score of 3.0 can be obtained for this
family.
Sequencing
The genomic structure of FZD6, MATN2, and SLC25A32 was determined using the
NCBI GenBank (www.ncbi.nlm.nih.gov). Forward and reverse primers were designed to
capture the sequence of each exon and approximately 50-100 bps upstream and downstream
of the intron/exon junction, as well as the complete 5’ and 3’ untranslated regions (UTRs)
for all three isoforms of FZD6, two isoforms of MATN2, and SLC25A32 (Supplemental
Tables 1-3). DNA samples from two affected family members (Fig 2: III-15 and IV-2) were
sequenced for each gene. These individuals were chosen from the opposite sides of the
family since they are less likely to share common familial variants. After initial data
analysis, 24 additional family members (5 affected and 19 unaffected) were sequenced for
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rs138557689 using FZD6 primer set E1C (Supplementary Table 1). Standard PCR
amplification conditions were used and the annealing temperatures for each primer set are
shown in the Supplemental Tables 1-3. Amplified PCR product was purified according to
manufacturer’s protocol (Qiagen, Valencia, CA). Sequencing results were compared to
consensus sequences obtained from NCBI public database and analyzed using Sequencer
v4.9 (Gene Codes, Ann Arbor, MI).
Variant Analysis
Sequence

variants

were

identified

using

dbSNP

(www.ncbi.nlm.nih.gov/projects/SNP). Only sequence changes shared by both affected
individuals (Fig 2: III-15 and IV-2) were considered. SNPs identified in the potential
regulatory regions, 5’ UTR and the first two introns of the gene, were assessed for their
effect on DNA binding using three online in silico analyses: Alibaba2, Patch, and
Transcription Element Search Software (TESS) [109,110,111].

SNPs identified in the

3’UTR region were assessed for their effect on microRNA binding sites using
microRNAMap and miRBAse databases [112,113]. SNPs identified in the coding region
were analyzed using PolyPhen and SIFT [114,115].
Species Conservation Analysis
SNPs were assessed for evolutionary conservation using the UCSC Genome Browser
Multiz Alignments of 46 Vertebrates track (www.genome.ucsc.edu/cgi-bin/hgGateway) and
the ECR Browser tool (http://ecrbrowser.dcode.org). SNPs were further assessed using the
genomic evolutionary rate profiling (GERP) track within the UCSC browser to estimate the
evolutionary constraint rates for individual nucleotide positions [116]. GERP scores are
positive in constrained regions and negative in neutral DNA [116].
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Electrophoretic mobility shift assay (EMSA)
EMSA was used to evaluate whether an ancestral or alternate allele in the SNP of
interest altered DNA binding.

20-mer oligonucleotide sequences were hybridized

incorporating either the ancestral or alternate allele (Integrated DNA Technologies,
Coralville, IA) and labeled with P32 dCTP (40,000cpm). The binding reaction was carried
out in 20 uL binding buffer mix (1M Tris (pH 7.5), 1M KCl, 80% glycerol, 10% NP-40,
0.5M EDTA, 100 mM PMSF, 1M DTT and H2O), containing 1 uL poly dGdC and 1 uL
Cos7 cell nuclear extract, and was incubated on ice for 20 mins. The sample was incubated
with the radiolabeled probes for 20 mins at room temperature.

The complexes were

resolved on a 5% polyacrylamide gel at 150V for 3hrs in TBE buffer. Gels were dried and
exposed at -80° C for 48 hrs. Negative controls were run with cold oligonucleotides using
the labeled probes and binding buffer without the nuclear extract.
Genotyping of NSCLP Probands and Unaffected Controls
A custom TaqMan Genotyping Assay (Applied Biosystems, Foster City, CA) was
designed to genotype rs138557689 using our standard protocol and was detected on ABI
Viia7 RUO Machine (Applied Biosystems, Foster City, CA). A total of 579 controls and
836 NSCLP probands were genotyped.

Allele calls were determined using the Viia7

Software (ABI) and the allele call rate was greater than 98%.

20

RESULTS
Sequencing of the coding and 5’ and 3’ UTR regions for FZD6, MATN2, and
SLC25A32 identified three sequence variants in III-15 and IV-2 (Fig. 4). One sequence
change, a homozygous deletion of nucleotide T (c.*164delT), was identified in the 3’UTR
of SLC25A32. This sequence variation is listed in dbSNP as rs11345830, but the frequency
in the general population was not available. However, this homozygous deletion is highly
conserved among primates, is not predicted to affect microRNA binding sites, and was
therefore excluded from further analysis. One variant, rs113199627 was identified in the
5’UTR of MATN2. This is a common variant in the population (MAF=14.5%) and was also
excluded from further analysis.
A single base pair c.-153+432A>C change in FZD6 was present in both individuals
(Fig. 4). Rs138557689, a SNP in intron 1, is located 681bps upstream of the start site.
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Based on the availability of DNA samples, 24 additional relatives were sequenced for the
same variant. The C allele was found to segregate with the cleft phenotype where 100% of
the affected individuals had the CA genotype (Fig 4: II-9, III-2, III-15, III-17, IV-2, IV-6,
IV-8). The C allele was transmitted by 4 unaffected individuals (Fig. 4: I-3, II-13, III-4, III11) and there were 5 other unaffected family members with the CA genotype (Fig. 4: II-12,
III-13, IV-5, IV-10, IV-12). The CA genotype was present in 60% of the unaffected family
members. There were no affected individuals, however, with the AA genotype.
Despite being submitted by the 1000 Genomes project and listed in NCBI, frequency
data on rs138557689 variant was not available. To assess the frequency of this allele, we
genotyped 579 controls of Non-Hispanic White (NHW), Hispanic, and African American
ethnicity, and found the C allele in 3 individuals (1 NHW and 2 African Americans) who
were heterozygous.

No homozygous individuals for the C allele were found.

The

frequency of the C allele was 0.8% in the African American, 0.3% in NHW, and 0% in
Hispanic controls (Table 2A). We then genotyped 836 probands from our NSCLP dataset
and found the C allele in
two

African

American

individuals, who were both
heterozygous.
includes

one

This
African

American proband from
the family described here.
The C allele was not found
in the NHW and Hispanic
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NSCLP probands. The frequency of the C allele in the NSCLP dataset was 1.2% for the
African Americans and 0% for the NHW and Hispanics (Table 2B).
To assess whether this SNP was in a conserved region, we compared the sequence
in different species. The ancestral A allele of rs138557680 showed conservation in chimps,
rhesus monkeys, gorillas, marmoset, mouse lemur, and opossum while the alternate C allele
was only conserved in elephants and armadillos (Fig. 5). These results suggest that C is a
rare variant.

The position of the rs138557689 variant showed moderate evolutionary

constraint (GERP score=-2.98). This suggests that the A allele is moderately conserved at
this location and that nucleotide changes at this position are tolerated and not selected
against through evolution.
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In silico analyses predicted that the alternate C allele alters DNA binding. The
ancestral allele was predicted to create a C/EB alpha transcription factor binding site by
Patch. The alternate allele was predicted to create a Sp1 site by AliBaba2, and NF-1/L
binding site by Patch and NIP and NF-1/L binding sites by TESS. EMSA analysis was used
to determine whether a DNA binding site was present with either allele. As shown in Fig. 6,
there were two bands present for the probe containing the C allele but not for the A allele.
These results indicate that the C allele creates new DNA binding sites.
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DISCUSSION
We identified a potentially functional variant, rs138557689, in intron 1 of FZD6
gene segregating with NSCLP phenotype in a large African American family. In silico
analysis suggested and EMSA results showed that the alternate C allele creates transcription
binding sites. Additionally, the ancestral A allele is highly conserved in primates and
moderately conserved in other vertebrates, suggesting that it may have important functional
significance in the regulation of FZD6. While the CA genotype for the rs138557689 variant
appears to contribute to the development of NSCLP in this family, analyses are underway to
assess how the variant affects gene expression.
The rs138557689/C allele is rare in the general population and was found in less than
1% of NHW and African American controls. The C allele was also rare in the NSCLP
probands being identified in only two of 1672 African American chromosomes. Even
though there appears to be an enrichment for the C allele in the African American
population in our data set, there was no significant difference in the C allele frequency
between the African American controls and NSLCP probands (p-value=1.0, Fisher exact
test). Based on this information the variant does not appear to be relevant at the population
level. However, the large number of individuals with the C allele in the African American
family suggests that the rare rs138557689/C genotype may act as a predisposing risk factor
for NSCLP when superimposed on the genetic background present in this family. The
presence of the C allele in the unaffected family members as well as controls suggests that a
person must have a specific combination of variants in one or multiple genes to exhibit the
phenotype. This is consistent with the multifactorial model and is supported by the observed
reduced penetrance in this African American family. Our results also suggest that different
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ethnic-specific genetic risk profiles may contribute to NSCLP, and therefore the underlying
disease mechanisms may also be different between ethnic groups. This is consistent with
the observed differences in prevalence of NSCLP among different populations and the
observed genetic heterogeneity that characterizes this complex disorder. Ethnic-specific
differences warrant further studies.
Variants in noncoding regions that modify transcription and expression have
increasingly been implicated in complex diseases because they perturb transcription by
creating or removing binding sites for specific transcription factors [21,117,118]. We found
that the presence of the rs138557689/C allele creates DNA binding sites that could
potentially repress or enhance the expression of FZD6. Because the development of facial
structures is a highly regulated process that relies on crosstalk and convergence of different
developmental pathways, alterations in the expression of FZD6 could affect the cascade of
molecular events that the gene is involved in.
While the exact function of FZD6 in human craniofacial development is not well
defined, FZD6 is diffusely expressed in the craniofacial mesenchyme of zebrafish and chick
suggesting that it plays a role during craniofacial development [119,120]. FZD6 is part of
the Frizzled family of genes which encode a group of G-coupled receptors critical for
initiation of WNT signaling [66,67]. WNT signaling is a highly controlled cellular pathway
that regulates multiple functions during development through both canonical/β-catenin and
noncanonical signal transduction [76,77]. Importantly, WNT signaling has been shown to
play a role in craniofacial development, including regional specification in the vertebrate
face, neural crest induction and differentiation, and mid-face development and upper lip
fusion in mice [26,80,81,82,83,84,85,121]. Craniofacial abnormalities, including orofacial
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clefts, are found in WNT knock-out mice and zebrafish, while mutations in WNT3 cause
tetra-amelia with CLP in humans [86,87,122]. Additionally, associations between WNTs
(WNT3, WNT3A, WNT5A, WNT7A, WNT8A, WNT9B and WNT11) and NSCLP have been
found, with strongest associations seen in WNT3 and WNT3A [87,88,89,90,123]. Unlike the
other Frizzleds, FZD6 represses canonical WNT signaling through the noncanonical
Ca2+/CaMKII pathway by down-regulating TCF/LEF binding activity and subsequent
transcription of WNT target genes (Fig. 7) [70].
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An increase in the expression of FZD6 may further repress canonical WNT signaling crucial
for normal craniofacial development while a decrease in FZD6 expression may cause a loss
of negative regulation of the WNT pathway. Negative regulation of the WNT pathway is
equally important in craniofacial development since mice that are deficient in the Dkk1 gene
(another negative regulator of the WNT pathway) lack craniofacial structures [124].
FZD6 has also been shown to mediate the non-canonical planar cell polarity
(WNT/PCP) pathway in mice (Fig. 7) [72,73,125]. The WNT/PCP pathway controls the
polarity and orientation of the migrating neural crest cells [81,126].

During normal

craniofacial development NCCs migrate from the neural folds to fill the facial prominences
with mesenchyme and contribute to the formation of the nose and upper lip
[20,26,28,127,128]. Defects in NCC formation, induction, differentiation, or migration can
result in craniofacial abnormalities [129,130,131,132].

Therefore, a decrease in FZD6

expression may perturb the WNT/PCP pathway and alter neural cell migration or
mesenchymal planar cell polarity in craniofacial structures and may potentially lead to
NSCLP.
In summary, we report that a rare genetic variant, rs138557689, which alters DNA
binding in FZD6, may act as a predisposing risk factor for NSCLP in a large African
American family with 11 cases of NSCLP segregating in 3 generations. The alteration in
FZD6 gene regulation may perturb highly controlled biological pathways, in particular the
WNT pathway, therefore focusing on the genes within the WNT pathway and their
interaction with FZD6 may provide further insight into the genetic etiology of NSCLP.
Assessing the affected and unaffected family members who have the CA genotype for the
presence of other variants in NSCLP susceptibility genes may delineate the underlying
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genetic risk profile contributing to development of NSCLP in this family. This outcome
would not only improve genetic counseling for this family but may improve the
understanding of the biological mechanisms linking FZD6 to NSCLP.
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APPENDIX

Supplementary Table 1. FZD6 Primers
Name

Forward

Reverse

Length (bp)

Tm(⁰C)

E1A

CACTGCTACCTGAGCATCCA

GGA AGC CAC CTC CAC CTT

318

65.1

E1B

AGA GCC AGC GCC AAG AGC TTC A

AGG GTG TAG TGC TGC CGT CGA AA

874

65.1

E1C

GGG AAC CGG CTC TGA AAG GCG

CCT TAA TAA GCT TTC CAA CAG GGG CCC

466

69.4

E1D

CTA GTT GGC CTT ACG AAA ATC GAG

GAC CCA GGA CTC ATT TTC AGG

514

60.2

E2

CAAATGTTGCTGATACACCCTC

CACAACTTGAAGAAATCGGCTC

473

54.3

E3

GAGTTCATAAGTCTGATAGAGGG

CTGTAAGTTCCCTGAGAGCAAG

544

54.3

E4A

CCCCATTAACAGCCACAAGTTTT

CGCCTAGCAAAAATCCAATGAAG

593

54.3

E4B

GCAACTCTGTTCACATTCCTTAC

GTACAAAGTAGCGAGAAGCATCC

481

54.3

E4C

GCAGTGTGGTTTCATGCTGTTG

GGCTCTTGTATTTTCTCACCTG

538

54.3

E5

GATAAAAAATGTGTTGCACTTAGAGC

GATAAAAAATGTGTTGCACTTAGAGC

486

54.3

E6A

CTGACAAAAGCAACTTAGAGTG

CCTCTCTCATTGATGTTTCTGG

472

54.3

E6C

GGTCATTTCCAAATCCATGGG

CAAACTTCCTTGGGGTAAGAG

427

54.3

E7A

GATAAAGGTGGACACTGGTTAG

GAAGATTCCTCTAACTCTGTCC

530

54.3

E7B

GCATTGCCTACTGTTATACTGG

GGACACTCTTTGAGTAAGCACC

592

54.3

E7C

CCCACTTATTGATACCTTACCATC

CAAAAGCATCAGAAAATCTTGCCC

576

54.3

E7D

GCCAATCAAATGGAAAAAAGGTAG

GCATTCTCCTTCAAGGTTAAAAAG

450

54.3

E=Exon
*Betaine was added to primer E1B during the PCR reaction.
*DMSO and magnesium chloride were added to primer E1C during the PCR reaction.
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Supplementary Table 2. MATN2 Primers
Name

Forward

Reverse

E1A

GCT ACT CTG AGG CAG GAG AAT GG

E1B

GAC TTT CCC TGC TCC CTC GGG GTA GG

E1C
E1D
E2

Tm(⁰C)

GGC TAA TTG ATG ACA AGC GCC AAG

Length
(bp)
572

C CGG GCG GAA GGA GGG GTG TCC

538

65.1

GGGAGCGCTCTGGGATGGGAC

CCT GTC CTC GGA GGG GTC GAA G

374

60.2

CAT CCCCGC GTC AGT GGG TGC

GAG GAC GGA GCC CCA GCT TCT

499

63.1

63.5

CGGCATTTTGAGTGCAAGTGG

CCAGCACATCCAACAAGGAC

417

63.5

E3A

GTAGAGACAGGGTTTTACAGTG

CCTCTGCTTCTGAGAATGCT

465

63.5

E3B

CGTGCTGTCAAGAGGATGCG

CCTATTGCCAGCACAGTACCTG

459

63.5

E4

CTGCCCAGAGGAGAGAGTAG

GGGATGATAACTGGGGTGGG

342

60.2

E5

GTTACTTTGGTGAGGGCTCTG

CTGAGCACTTTGTGGAAACCC

352

63.5

E6

GCCCTCATCCTACCATTCCC

GTTGAGATACAGTGGTCTATGGTC

383

63.5

E7

CCCCTTCATGGTGTGACTC

GCTTAAGATTTGCACGGAAAGG

338

60.2

E8

GAATGATCCGTCCCGGCTTG

GACCATCAGGAAACCCGGTG

375

63.5

E9

GACACCTTCCCTGTGGCTTG

GACACCTTCCCTGTGGCTTG

305

63.5

E10

GCATGCCTTCGAGGGAGGGC

GGCCCAGCAAAGCCTGGAGAC

315

63.5

E11

GGCCCAGCAAAGCCTGGAGAC

CCATTTTCTCTTTCAGGGTCC

400

60.2

E12

CCATGGACCACTGAGCTCAGG

GAGCACCCAAGGCAGGAACTG

379

63.5

E13

CCCCATCCTGAGTATGAGAC

GCAGTTAAGCCCTCTCTTCC

440

63.5

E14

GGTTCCCCAAAGTGGTTATGCC

CTGTACACTCAAAGAAGCTTACCC

625

63.5

E15

GTTGGCATGGACTCTTCAAATC

GCTGAAGCATGAGAATCACTTG

446

63.5

E16

GCTTTTTTGAATCTTTGGTGTTACC

GTAAATGTTAACTATCTTTTTGAGGG

372

63.5

E17

CCAAGTGCTAGGAATACCAAG

CTATTTCCTACTTCCTTCTTTCC

338

56.2

E18

GGTATTTACTGGATCTGGCTGC

CTTGCCCTTGCCTCTCAAAC

425

63.5

GAG TTC TAC AAA TTT ACA AGT CAG
GG
GTGAGAATGAATAAGCTATGCAAG

CA AAT GAG ATT GCA CAC TAA GGC

542

56.2

CCACATCCTTACCAACACTTG

562

62

GAG AAA TGG CCA ACA TGC CTA TGA
AAA AAA TGC TG

CTA CAG GCA CCC ACT ACC ACA CCC G

595

68.2

E19A
E19B
E19C

E=Exon
DMSO and magnesium chloride were added to primer E2 during the PCR reaction.
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Supplementary Table 3. SLC25A32 Primers
Name
E1A
E1B

Forward

Reverse

Length (bp)

Tm(⁰C)

CAT CTC GGT TGC TCT TCC GGC

CGC CCC TTG TGA GCG CAA C

431

67

CCC CTC CAT CGC GCT TTC CG

CAG GTT AGC CAA CGC GGA CAG

513

67

E2

CGG GAC TCT GAC ACA AAA ATG

GCC ATT TTG TTC TTC CTG ATC C

519

62

E3

GCA AAC CAC TTC CAG CAA ATT C

CTG AGG CAG GAT TAT CGC TTG

530

58.3

E4

CCT TTT GAC CCT AAG ACT GTG C

GAT ACA TCC TAT GTT AAT GGG GAC

537

58.3

E5

GTG CTG TAA TGA GAG AGA AGA G

GAC ATT TGT GTG GCT TCA

374

58.3

E6

GAT GAG TAC TGG CTC TGC CA

CGT AAT AAC TGG GAA AGC AGG

473

58.3

E7A

GAC TGC TGC TTG CTC CAT GCC

GGC AGC CAT TTC AGG CAG AGG

454

58.3

E7B

GAA GCC AGA GAA CTG CTA AGT C

CGA CAA AGC AAG ACT CCA TCT C

404

62

E7C

GTG AGC TTA CTT GCC TGG ATT GC

CGC TAG GTA GTG CAT CCC AAC TG

543

62

E7D

GGATGGTCTCAATCTCCTGAC

CAA CCT GAA TTT GAG AAA CCA ATG AAG

564

58.3

E7E

GTTGACAAGGTAAATGGAAATGAG

GTT CAC TTT TTC CGT GTG GGG

517

58.3

E7F

GCT GTT GCA CTA CCA TCT ATT TG

CTC AGT GCT TGG TGA CGT AC

556

52

E=Exon
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